Aurobindo Pharma re-appoints Girish Paman Vanvari to its Board

Girish Paman Vanvari

Aurobindo Pharma Limited announced the re-appointment of Girish Paman Vanvari as an Independent Director on the company’s Board, with effect from November 5, 2022.

According to the company’s exchange filing, “We hereby inform that based on the recommendation of Nomination, Remuneration and Compensation Committee and subject to the approval of the members of the Company by way of special resolution through Postal Ballot, the Board of Directors of the Company approved today, 14th December 2022, the reappointment of Mr. Girish Paman Vanvari (DIN: 07376482) as an Independent Director of the Company for the second term of 5 (five) consecutive years w.e.f. 5 th November 2022.”

Girish Paman Vanvari is a Fellow member of the Institute of Chartered Accountants of India with around three decades of consulting experience. He is the Founder of Transaction Square – a Tax, Regulatory and Business Advisory firm.

Prior to his entrepreneurial venture, Girish had a 13 year stint with KPMG wherein he was the National Leader for Tax at KPMG India. He has regularly worked with many large multinationals and Indian promoter companies in advising them on various tax and regulatory issues. Further, he has built an exclusive legacy of work in M&A deals and restructuring transactions for some of the biggest deals in the industry.

Prior to KPMG, Girish was at Arthur Andersen for over a decade. Girish is a regular conference host, presenter and moderator at various tax conferences and seminars. He has been regularly featured in a number of international and Indian media outlets, newspapers and business magazines.

+ posts

HrNxt.com Newsdesk has researchers and writers with an excellent domain knowledge about the talent ecosystem, and the business environment. The team keeps a tab on the latest happenings in the ecosystem to bring most relevant news and insights for our readers. You can connect with our newsdesk at newsdesk@hrnxt.com.

What's your take on this post ? Comment: